Zhiye Zhang

机构：Jilin Normal University, Anhui Medical University, Zhejiang Ocean University, Jilin Engineering Normal University, Zhejiang Marine Fisheries Research Institute, First Affiliated Hospital of Henan University of Science and Technology, First Hospital of Lanzhou University, Lanzhou University · ORCID：0000-0002-1661-2277

发表论文 253 篇 · 总被引 5755 次 · h-index 41

代表论文

• Sacituzumab tirumotecan versus docetaxel for previously treated EGFR -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial (2025 · BMJ · 被引 41)
• Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial (2025 · The Lancet · 被引 33)
• Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies (2025 · Signal Transduction and Targeted Therapy · 被引 14)
• Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial (2025 · European Journal of Cancer · 被引 11)
• Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study. (2025 · Journal of Clinical Oncology · 被引 10)
• Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial (2025 · Molecular Cancer · 被引 9)